Monoclonal IgM Gammopathy and Waldenstr öm's Macroglobulinemia.
CONCLUSION: Evidence-based treatment decisions in Waldenström's macroglobulinemia now rely mainly on small-scale, single-armed trials. Patients with this disease should be treated in the setting of a clinical trial if possible. Trials aimed at improving the quality of treatment for other IgM-associated diseases, such as IgM neuropathies and cold agglutinin disease, would also be desirable.
PMID: 29169431 [PubMed - in process]
Source: Deutsches Arzteblatt International - Category: General Medicine Tags: Dtsch Arztebl Int Source Type: research
More News: Brain | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | General Medicine | Germany Health | Macroglobulinemia | Myeloma | Neurology | Rituxan | Waldenstrom's Macroglobulinemia